Key Metrics of 10X Genomics
Revenue$619M▲ 19.8% YoYFY 2023
Operating income−$265M▼ 58.0% YoY
Net profit−$255M▼ 53.7% YoY
Shareholders' equity$741M
Market cap$9.1BTXG · $69.75
Competitors10identified
About 10X Genomics
Sectors
Company details
- Website
- 10xgenomics.com
- Founded
- 2019
- Listed
- Nasdaq: TXG (since 2019)
Operational Areas of 10X Genomics
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal name10x Genomics Inc.
TickerTXG
ExchangeNasdaq
CountryUnited States
SEC CIK0001770787
Listed since2019
IndustryBiotechnology: Laboratory Analytical Instruments
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttps://www.10xgenomics.com
US market & SEC filings
TXG · Nasdaq · SEC CIK 0001770787
Last price · 24 Oct 2026
$69.75
−7.73%
Market cap$9.1B
P/E—On FY 2023 diluted EPS
Volume4,190,336
SectorIndustrialsBiotechnology: Laboratory Analytical Instruments
Country · IPOUnited StatesListed 2019
TXG share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officePleasanton
GSTIN—
Email—
Websitehttps://www.10xgenomics.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of 10X Genomics
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
biotechnology industry
Filings
No filings on record yet.